If this message is not displayed correctly, click here.

 

No 116, November 2017

 
Image

New on ENP! Hyperkalaemia in CKD: An Evolving Treatment Landscape

This review addresses the current status of hyperkalaemia treatment and offers a condensed summary of the AstraZeneca lunch symposium that was held at the 54th ERA-EDTA Congress in Madrid (Spain). Do not miss the opportunity to read the review article here.


A new NDT-Educational Summary Report of the 54th ERA-EDTA Congress is now accessible through ENP.

A new NDT-Educational Summary Report of the 54th ERA-EDTA Congress (Madrid, Spain) based on Prof. Jack F.M. Wetzels's presentation “Personalized monitoring and treatment in membranous nephropathy”! Click here to read it.

Image

Diabesity disseminating knowledge on diabetes and obesity related nephrology

Diabesity, an official Working Group of the ERA-EDTA, was founded (in 2013) with the specific aim of creating and disseminating knowledge on the nephrological impact of Diabetes and Obesity. Thanks to the collaborative efforts of its members, in 2015 Diabesity launched the European Nephrectomy Bio-BAnk (ENBIBA), a bio bank of unaffected renal tissue from nephrectomies aimed at evaluating renal histology changes in patients with obesity, unhealthy-obesity and diabetes in the early stages. The project involves 10 EU centres (Spain, Portugal, Italy, Slovenia) and has recruited more than 250 cases.

Diabesity is also promoting educational activities on a yearly basis. This year Diabesity is organising an interesting CME on ‘Renal disease in obesity and diabetes. Advances in pathogenesis and therapeutics’ that will be held on November 24-25, 2017 in Lisbon (Portugal). At this meeting new advances in the pathogenesis and treatment of diabetes and obesity in renal disease will be addressed and, furthermore, preliminary analyses related to ENBIBA will be presented.

 
NDT and CKJ articles

Just published online! Read the latest NDT and CKJ articles

Nephrology goes Social Media – a development you cannot ignore!

Social Media has changed the game for the medical community – and the authors of this “NDT Digest” article encourage everyone to jump in. Professional organizations have started to develop social channels to update members and users and build interactive communities – as ERA-EDTA has been successfully doing. National and international meetings, including the ERA-EDTA Congresses, are now routinely discussed and reported in real time by social media users who are actually attending. Almost all medical journals – and also NDT and CKJ – now promote articles through social media, and last but not least, the ‘altmetric’ scoring is becoming increasingly important. It must also be underlined that the patients use social media to get information as well as emotional and network support. In conclusion, social media is everywhere and cannot be ignored by nephrologists. The authors of this article ask all to maintain professional standards when interacting with others on social networks, but, in this case, they believe that the benefit outweigh any perceived risks.

Low-dose RTX is efficient and cost-saving in treatment of patients with idiopathic membranous nephropathy

Rituximab (RTX) therapy is effective in the treatment of idiopathic membranous nephropathy (IMN). Various studies have shown that it lowers proteinuria and, thus, the risk of progression to end-stage kidney disease. However the other side of the coin is that the treatment costs are high. For this reason a study published in CKJ aimed at assessing the efficacy and safety of low-dose RTX in patients with immunosuppression-resistant IMN. The patients received two doses of RTX (500 mg each) infusion 7 days apart. Although they were difficult to treat and prior immunosuppressive therapy had failed, 61.9% patients achieved remission during a median follow-up of 13 months in this study. The authors admit that a follow-up period of 13 months was rather short and the study, being retrospective, had some limitations, however this analysis gives encouraging results to initiate further studies.

Low-dose RTX is efficient and cost-saving in treatment of patients with idiopathic membranous nephropathy

Rituximab (RTX) therapy is effective in the treatment of idiopathic membranous nephropathy (IMN). Various studies have shown that it lowers proteinuria and, thus, the risk of progression to end-stage kidney disease. However the other side of the coin is that the treatment costs are high. For this reason a study published in CKJ aimed at assessing the efficacy and safety of low-dose RTX in patients with immunosuppression-resistant IMN. The patients received two doses of RTX (500 mg each) infusion 7 days apart. Although they were difficult to treat and prior immunosuppressive therapy had failed, 61.9% patients achieved remission during a median follow-up of 13 months in this study. The authors admit that a follow-up period of 13 months was rather short and the study, being retrospective, had some limitations, however this analysis gives encouraging results to initiate further studies.

 

The 4C Study for the care of Children and Adolescents

The ERA-EDTA Research Programme was created (in 2009) to contribute to the establishment of high level European networks of Research. Among the research projects funded by ERA-EDTA, the ‘4C Study’, with Prof. Franz Schaefer (Heidelberg, Germany) as principle investigator, helped taking a step forward the investigation of cardiovascular and renal risk of children and adolescents with CKD.

The 4C Study enrolled a total of 704 children and adolescents with chronic kidney disease (CKD) in 2010/11 in 54 pediatric nephrology centres in 12 European countries.

The study showed that the RRT modality had a significant impact on the change in arterial structure and function. The findings suggest that pre-emptive transplantation can prevent further deterioration of the subclinical vascular organ damage early after transplantation. In addition to these important insights regarding the early development of cardiovascular morbidity, the study identified several markers and potential mechanisms of renal disease progression in children with CKD.

 
 
 
 
ERA-EDTA: Innovation and Education in Kidney Science and Care.
Web Site
 
secretariat@era-edta.org
 
 
Facebook
 
Twitter
 
Google+
 
LinkedIn
 
Instagram
 
YouTube
 
Vimeo
 

ERA-EDTA Flash is the official ERA-EDTA eNewsletter

Editor-in-Chief: Mustafa Arici
Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters
Via XXIV Maggio, 38
43123 Parma - Italy

 

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.